Halozyme Therapeutics (NASDAQ:HALO) Sets New 52-Week High – Here’s What Happened

Posted by Brian Himes on Aug 6th, 2026

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $84.49 and last traded at $83.8980, with a volume of 28401 shares trading hands. The stock had previously closed at $83.59.

Analyst Ratings Changes

Several brokerages have recently commented on HALO. Morgan Stanley lowered their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. UBS Group reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Weiss Ratings raised shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, July 31st. Finally, HC Wainwright reiterated a “buy” rating and set a $95.00 target price on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Eight equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $81.60.

Check Out Our Latest Stock Report on HALO

Halozyme Therapeutics Price Performance

The company has a market capitalization of $9.89 billion, a price-to-earnings ratio of 29.95, a price-to-earnings-growth ratio of 0.34 and a beta of 0.85. The company has a 50-day moving average price of $75.39 and a 200-day moving average price of $71.15. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last announced its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. The business had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. Halozyme Therapeutics’s revenue for the quarter was up 42.2% on a year-over-year basis. During the same period last year, the company posted $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, equities research analysts expect that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total transaction of $124,653.75. Following the transaction, the director directly owned 42,044 shares of the company’s stock, valued at $3,225,195.24. This trade represents a 3.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 1,923 shares of the business’s stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $79.77, for a total transaction of $153,397.71. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $61,245,810.60. This trade represents a 0.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 72,477 shares of company stock valued at $5,102,643. Corporate insiders own 2.50% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Arrowstreet Capital Limited Partnership lifted its holdings in Halozyme Therapeutics by 29.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock worth $241,337,000 after acquiring an additional 749,484 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Halozyme Therapeutics by 1.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock worth $141,613,000 after acquiring an additional 25,731 shares in the last quarter. Norges Bank bought a new stake in shares of Halozyme Therapeutics in the fourth quarter worth about $128,201,000. William Blair Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter worth about $124,031,000. Finally, Federated Hermes Inc. raised its position in shares of Halozyme Therapeutics by 8.5% during the fourth quarter. Federated Hermes Inc. now owns 1,574,621 shares of the biopharmaceutical company’s stock worth $105,972,000 after purchasing an additional 123,917 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

(Get Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.